fda tirzepatide compounding warning 2024 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Announced Removal of Tirzepatide

The gap between doing it right and stopping at week six due to unbearable side effects comes down to understanding why the escalation schedule exists

Metabolic pathways promoting cancer cell survival and growth

Incorporate them into meals for a nutritious option that supports weight management and metabolic health

Accepting unwanted experiences can alleviate diabetes distress, which stems from the daily burdens of self-care

van Kaam, MD, PhD, neonatologist, Emma Childrens Hospital, Amsterdam University Medical Centers, location University of Amsterdam, Department of Neonatology, Amsterdam Reproduction & Development, Amsterdam, the Netherlands

Treatments that mimic GLP-1 can assist with type 2 diabetes and weight management, but consulting with a healthcare provider is essential before starting